Advertisement

Advertisement

AVIR Stock Latest News

Atea Shareholders Back Directors, Auditors and Executive Pay

Company AnnouncementsAtea Shareholders Back Directors, Auditors and Executive Pay

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call

PremiumCompany Announcements

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call

1M ago

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI

PremiumThe Fly

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI

4M ago

Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026

PremiumCompany Announcements

Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026

4M ago

Is AVIR a Buy, Before Earnings?

PremiumPre-Earnings

Is AVIR a Buy, Before Earnings?

4M ago

Atea Pharmaceuticals presents preclinical results of AT-587

PremiumThe FlyAtea Pharmaceuticals presents preclinical results of AT-587

4M ago

Atea Pharmaceuticals to highlight strategic priorities for FY26

The Fly

Atea Pharmaceuticals to highlight strategic priorities for FY26

6M ago

Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

The Fly

Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

6M ago

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

PremiumCompany Announcements

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

7M ago

Atea Pharmaceuticals Advances Antiviral Programs with New Data

PremiumCompany Announcements

Atea Pharmaceuticals Advances Antiviral Programs with New Data

7M ago

AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

7M ago

Atea Pharmaceuticals announces presentation of data on BEM, RZR

PremiumThe Fly

Atea Pharmaceuticals announces presentation of data on BEM, RZR

8M ago

Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?

PremiumCompany AnnouncementsAtea Pharmaceuticals’ New HCV Study: Potential Game-Changer?

8M ago

Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir

Company Announcements

Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir

8M ago

Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors

Company Announcements

Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors

8M ago

Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

PremiumThe Fly

Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

9M ago

Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress

PremiumCompany Announcements

Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress

10M ago

Atea Pharmaceuticals Advances in HCV Treatment Development

PremiumCompany Announcements

Atea Pharmaceuticals Advances in HCV Treatment Development

11M ago

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

PremiumThe Fly

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

12M ago

Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting

PremiumCompany AnnouncementsAtea Pharmaceuticals Holds 2025 Annual Stockholders Meeting

1y ago

Atea Pharmaceuticals Advances HCV Treatment Trials

Company Announcements

Atea Pharmaceuticals Advances HCV Treatment Trials

1y ago

AVIR Upcoming Earnings Report: What to Expect?

Pre-Earnings

AVIR Upcoming Earnings Report: What to Expect?

1y ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >